## Corinne Arpin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/282296/publications.pdf

Version: 2024-02-01

		304743	377865
34	1,974	22	34
papers	citations	h-index	g-index
35	35	35	2634
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Oligonucleotide Solid Nucleolipid Nanoparticles against Antibiotic Resistance of ESBL-Producing Bacteria. Pharmaceutics, 2022, 14, 299.	4.5	3
2	Lipid oligonucleotides as a new strategy for tackling the antibiotic resistance. Scientific Reports, 2020, 10, 1054.	3.3	23
3	MgrB Inactivation Is Responsible for Acquired Resistance to Colistin in Enterobacter hormaechei subsp. steigerwaltii. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	11
4	Experimental evidence for IS1294b-mediated transposition of the blaCMY-2 cephalosporinase gene in Enterobacteriaceae. Journal of Antimicrobial Chemotherapy, 2015, 70, 697-700.	3.0	23
5	NDM-1-Producing Klebsiella pneumoniae Resistant to Colistin in a French Community Patient without History of Foreign Travel. Antimicrobial Agents and Chemotherapy, 2012, 56, 3432-3434.	3.2	43
6	Duplication of the chromosomal bla SHV-11 gene in a clinical hypermutable strain of Klebsiella pneumoniae. Microbiology (United Kingdom), 2011, 157, 496-503.	1.8	16
7	Activity of Linezolid in an <i>In Vitro</i> Pharmacokinetic-Pharmacodynamic Model Using Different Dosages and <i>Staphylococcus aureus</i> and <i>Enterococcus faecalis</i> Strains with and without a Hypermutator Phenotype. Antimicrobial Agents and Chemotherapy, 2010, 54, 1443-1452.	3.2	12
8	CTX-M-producing Escherichia coli in a maternity ward: a likely community importation and evidence of mother-to-neonate transmission. Journal of Antimicrobial Chemotherapy, 2010, 65, 1368-1371.	3.0	39
9	A Multinational Survey of Risk Factors for Infection with Extendedâ€Spectrum βâ€Lactamase–Producing Enterobacteriaceae in Nonhospitalized Patients. Clinical Infectious Diseases, 2009, 49, 682-690.	5.8	415
10	Role of the AheABC Efflux Pump in <i>Aeromonas hydrophila </i> Intrinsic Multidrug Resistance. Antimicrobial Agents and Chemotherapy, 2008, 52, 1559-1563.	3.2	46
11	Â-Lactam and aminoglycoside resistance rates and mechanisms among Pseudomonas aeruginosa in French general practice (community and private healthcare centres). Journal of Antimicrobial Chemotherapy, 2008, 62, 316-323.	3.0	51
12	Molecular and Biochemical Characterization of SHV-56, a Novel Inhibitor-Resistant $\hat{l}^2$ -Lactamase from < i>Klebsiella pneumoniae < /i>. Antimicrobial Agents and Chemotherapy, 2008, 52, 3792-3794.	3.2	23
13	Synthesis of Omeprazole Analogues and Evaluation of These as Potential Inhibitors of the Multidrug Efflux Pump NorA of Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2007, 51, 831-838.	3.2	72
14	High Genetic Stability of Integrons in Clinical Isolates of Shigella spp. of Worldwide Origin. Antimicrobial Agents and Chemotherapy, 2007, 51, 1333-1340.	3.2	46
15	Extended-Spectrum- $\hat{I}^2$ -Lactamase-Producing Enterobacteriaceae Strains in Various Types of Private Health Care Centers. Antimicrobial Agents and Chemotherapy, 2007, 51, 3440-3444.	3.2	14
16	Synthesis of new 4-[2-(alkylamino)ethylthio]pyrrolo[1,2- <i>a</i> ]quinoxaline and 5-[2-(alkylamino)ethylthio]pyrrolo[1,2- <i>a</i> ]thieno[3,2- <i>e</i> ]pyrazine derivatives, as potential bacterial multidrug resistance pump inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2007, 22, 620-631.	5.2	14
17	Activity of Gatifloxacin in an In Vitro Pharmacokinetic-Pharmacodynamic Model against Staphylococcus aureus Strains either Susceptible to Ciprofloxacin or Exhibiting Various Levels and Mechanisms of Ciprofloxacin Resistance. Antimicrobial Agents and Chemotherapy, 2006, 50, 1931-1936.	3.2	20
18	TEM-21 extended-spectrum $\hat{I}^2$ -lactamase in a clinical isolate of Alcaligenes faecalis from a nursing home. Journal of Antimicrobial Chemotherapy, 2006, 57, 368-369.	3.0	14

#	Article	IF	CITATIONS
19	Prolonged Outbreak of Infection Due to TEM-21-Producing Strains of Pseudomonas aeruginosa and Enterobacteria in a Nursing Home. Journal of Clinical Microbiology, 2005, 43, 4129-4138.	3.9	32
20	Clinical and Molecular Analysis of Extended-Spectrum β-Lactamase-Producing Enterobacteria in the Community Setting. Journal of Clinical Microbiology, 2005, 43, 5048-5054.	3.9	42
21	SHV-49, a Novel Inhibitor-Resistant $\hat{l}^2$ -Lactamase in a Clinical Isolate of Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2004, 48, 4466-4469.	3.2	29
22	Activities of Ciprofloxacin and Moxifloxacin against Stenotrophomonas maltophilia and Emergence of Resistant Mutants in an In Vitro Pharmacokinetic-Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2004, 48, 946-953.	3.2	46
23	TbtABM, a multidrug efflux pump associated with tributyltin resistance inPseudomonas stutzeri. FEMS Microbiology Letters, 2004, 232, 7-14.	1.8	55
24	Decreased Susceptibility to Cefepime in a Clinical Strain of Escherichia coli Related to Plasmid- and Integron-Encoded OXA-30 β-Lactamase. Antimicrobial Agents and Chemotherapy, 2003, 47, 2380-2381.	3.2	42
25	Extended-Spectrum $\hat{I}^2$ -Lactamase-Producing Enterobacteriaceae in Community and Private Health Care Centers. Antimicrobial Agents and Chemotherapy, 2003, 47, 3506-3514.	3.2	130
26	Molecular Characterization of a Novel Class 1 Integron Containing bla GES-1 and a Fused Product of $aac(3)$ -lb/ $aac(6")$ -lb" Gene Cassettes in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2002, 46, 638-645.	3.2	128
27	Clinical Strain of Pseudomonas aeruginosa Carrying a bla TEM-21 Gene Located on a Chromosomal Interrupted Tn A Type Transposon. Antimicrobial Agents and Chemotherapy, 2002, 46, 3624-3626.	3.2	31
28	Cross-Infection Due to Imipenem-Resistant Bacteroides fragilis Associated with a Totally Implantable Venous Port. Journal of Clinical Microbiology, 2002, 40, 3032-3034.	3.9	8
29	Type II Topoisomerase Quinolone Resistance-Determining Regions of Aeromonas caviae , A. hydrophila, and A. sobria Complexes and Mutations Associated with Quinolone Resistance. Antimicrobial Agents and Chemotherapy, 2002, 46, 350-359.	3.2	62
30	TEM-80, a Novel Inhibitor-Resistant $\hat{l}^2$ -Lactamase in a Clinical Isolate of Enterobacter cloacae. Antimicrobial Agents and Chemotherapy, 2002, 46, 1183-1189.	3.2	17
31	SHV-16, a $\hat{I}^2$ -Lactamase with a Pentapeptide Duplication in the Omega Loop. Antimicrobial Agents and Chemotherapy, 2001, 45, 2480-2485.	3.2	21
32	Nosocomial Outbreak Due to a Multiresistant Strain of Pseudomonas aeruginosa P12: Efficacy of Cefepime-Amikacin Therapy and Analysis of $\hat{l}^2$ -Lactam Resistance. Journal of Clinical Microbiology, 2001, 39, 2072-2078.	3.9	68
33	Impact of an Urban Effluent on Antibiotic Resistance of Riverine <i>Enterobacteriaceae</i> and <i>Aeromonas</i> spp. Applied and Environmental Microbiology, 2000, 66, 125-132.	3.1	330
34	Emergence of mefA and mefE genes in beta-haemolytic streptococci and pneumococci in France. Journal of Antimicrobial Chemotherapy, 1999, 44, 133-134.	3.0	45